Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer



Summary

Rechallenge with immune checkpoint inhibitors (ICIs) in advanced lung cancer patients who initially benefited but later progressed is a growing area of interest. Studies suggest that a subset of patients may experience renewed benefit from ICI re-exposure, particularly those with a prolonged treatment-free interval between ICI treatments. Factors like PD-L1 expression, tumor mutational burden, and the nature of initial response could predict the likelihood of success. While rechallenge can offer an alternative for patients with limited options, careful patient selection and monitoring for immune-related adverse events are crucial. More research is needed to identify optimal rechallenge strategies and predictive biomarkers.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!